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Dialysis of methylguanidine
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Dialysis of methylguanidine. The dialysis clearance of methyl-
guanidine (MG) was measured in Vitro and in ViVo; the fall in its
plasma concentration was measured after peritoneal dialysis
and hemodialysis in uremic patients and on plasma and muscle
tissue of uremic dogs; the postdialysis plasma rebound was
evaluated after hemodialysis and peritoneal dialysis; and,
finally, MG binding to plasma proteins was measured in vitro at
different pH values. The dialysis clearance of MG was lower in
vivo than in vitro and it decreased during the course of hemo-
dialysis. Its protein binding, rising as the plasma pH rose during
hemodialysis, accounted for its dialytic behavior. The slow
transfer of MG from tissue, occurring during dialysis as shown
by the experiments on uremic dogs, accounted for its high
rebound in plasma after hemodialysis. Rebound after peritoneal
dialysis was lower so that the MG plasma concentrations, 12 hr
after the end of two dialytic procedures, were not different. It is
concluded that MG is the only known "uremic toxin" thus far
studied whose dialytic removal is equally obtained with both
peritoneal dialysis and hemodialysis schedules which insure that
the patient is maintained in good clinical condition.
La dialyse de Ia mdthylguanidine. La clearance de Ia methyl-
guanidine (MG) au cours de la dialyse a été mesurée in vivo et in
vitro. La diminution de la concentration plasmatique aprCs
dialyse péritonéale et hémodialyse a été mesurée chez les
malades urémiques et dans le plasma et le tissu musculaire de
chiens urémiques. Le rebond post dialytique a etC CvaluC après
hemodialyse et dialyse péritonéale. Enfin la liaison de MG aux
protéines a Cté mesurée in vitro pour différentes valeurs du pH.
La clearance de MG au cours de Ia dialyse est inférieure in vivo
a ce qu'elle est in vitro et diminue au cours de l'hCmodialyse. La
liaison aux protéines, qui augmente en même temps au le pH
s'élève au cours de l'hémodialyse, rend compte de ce comporte-
ment dialytique. Le transfert lent de MG des tissus qui survient
pendant l'hémodialyse, ainsi que le montrent les experiences
chez le chien, rend compte du rebond post dialytique élevé. Les
rebonds aprés dialyse péritonéaie sont plus faibles si bien que la
concentration plasmatique de MG est semblable 12 heures
aprés la fin de chacun des deux modes de dialyse. Ii est conclu
que la MG est la seule "toxine urémique" connue, et étudiée
jusque là, dont Ia soustraction par dialyse Soit obtenue dans des
conditions égales aussi bien avec la dialyse péritonéale que
l'hémodialyse dans des conditions qui assurent un état clinique
satisfaisant.
Methylguanidine (MG) administered repeatedly to
normal dogs in large doses has been found to induce
Received for publication October 9, 1973;
and in revised form March 14, 1974.
© 1974, by the International Society of Nephrology.
177
symptoms resembling those of uremia, such as anemia,
anorexia, vomiting, gastric ulcers, peripheral neuro-
pathy, decreased intestinal absorption of calcium and
hypertriglyceridemia [1, 2]. When smaller doses were
used, so as to maintain MG plasma concentrations at
values resembling those of chronically ill nondialyzed
uremic patients (300 to 500 g/lO0 ml), similar but
milder symptoms were induced [3].
These findings suggest that the retention of MG in
renal failure may provide an important source of
"uremic toxin", but this possibility stands in sharp
contrast with "the middle molecule hypothesis"
which states that the toxic symptoms of uremia
may be caused by substance(s) with a mol wt
between 300 and 1000 [4]. The latter hypothesis is
mainly supported by the observation that uremic
patients on maintenance peritoneal dialysis [5] or
hemodialysis at a low dialysate flow rate [6, 7] respond
as well to treatment as do those on a standard hemo-
dialysis program, despite the fact that the plasma
concentrations of the low mol wt metabolites such as
urea (U; mol wt, 60) and creatinine (CR; mol wt, 113)
are higher in the former patients.
A logical explanation for this clinical finding might
be provided by the existence of toxic molecules of
intermediate mol wt which would pass more readily
through the peritoneal membrane than through
cellophane, and whose removal would not be de-
creased during hemodialysis at low rates of dialysate
flow [4].
One would expect that MG, having a mol wt (73)
which is intermediate between that of U and CR,
would accumulate in the body fluids of patients on
peritoneal dialysis or hemodialysis at low dialysate
flow rate and that, if so, such an event would provide a
strong argument against its proposed importance as a
"uremic toxin".
In the present study this problem has been examined
by measuring the dialyzer clearance rates of MG in
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vitro and in uremic patients; by measuring its dialytic
removal from 40 liters of "artificial uremic blood"
and its decrease in concentration in the plasma of
uremic patients subjected to peritoneal dialysis or
hemodialysis from plasma and muscle tissue of uremic
dogs; by measuring the rebound of its plasma con-
centration 12 hr after the termination of hemodialysis
and peritoneal dialysis; and, finally, by evaluating its
binding to plasma proteins at different pH values.
Methods
The uremic patients we examined had received
maintenance dialysis for at least three months prior to
this study; all were anuric or extremely oliguric (less
than 100 ml of urine/24 hr) with an endogenous
creatine clearance less than 2 ml/min. In addition,
studies were also carried out on six mongrel dogs in
which uremia was induced via bilateral ureteral
ligation.
The "artificial uremic blood" employed in the in
vitro experiments was a water-based solution of U
(about 250 mg/100 ml), CR (about 15 mg/lO0 ml) and
MG (about 250 g/l00 ml). For measurements of
dialyzer clearance rates in vitro (six experiments), this
solution was recirculated at 200 mI/mm for 12 hr,
through a two-layer Kiil dialyzer assembled with a
"150 P" Cuprophane membrane. Dialysate, con-
sisting of tap water, was circulated in "single pass"
and the temperature of both the "artificial uremic
blood" and dialysate was maintained at 37°C. The
various flow rates of dialysate (Fig. 1) were measured
on the outflow line with a graduated cyclinder and
chronometer. The same artificial kidney and type of
membrane were employed for measurements of the
dialyzer clearance of MG on uremic patients (nine
experiments). Both in vitro and in vivo, these mea-
surements were made 20 mm after the beginning of
dialysis and at the 4th, 8th and 12th hr. Two rates of
dialysate flow (QD) were examined in vivo: 200 and
500 ml/min, while the blood flow rate (QB) was
maintained as constant as possible at 200 ml/min by
means of a blood pump. The "air bubble" method
was also employed as an additional determinant of
the rate of blood flow when clearance rates were
measured.
For both in vitro and in vivo measurements of
dialyzer clearances, as well as for those during
peritoneal dialysis, the following formula [8] was
employed:
= CD.QD,
where CD and CD are the concentrations of the
examined metabolite in dialysate and arterial blood,
respectively.
The predialysis and postdialysis concentrations of
U, CR and MG were measured in the following con-
ditions: 1) on 40 liters of "artificial uremic blood"
circulating for eight hours through a multipoint
dialyzer (assembled with "150 P" Cuprophane mem-
brane) at QB 250 and QD750 ml/min (five experiments);
2) on the plasma of 28 uremic patients on an inter-
mittent program consisting of two dialyses per week
carried out with a multipoint dialyzer under the same
conditions as the in vitro experiments; 3) on the
plasma of eight uremic patients on a program of two
dialyses per week of 12 hrs' duration carried out with
a standard two-layer Kiil dialyzer at QB 200 and QD
500 ml/min; 4) on the plasma samples of 11 uremic
patients on twice-weekly peritoneal dialysis of 18 to
20 hrs' duration each, with a total dialysate exchange of
80 to 100 liters; and 5) on the plasma and muscle tissue
of six dogs on the third day of anuria following liga-
ture of the ureters. These animals were dialyzed for
six hours with a standard two-layer Kiil kidney utiliz-
ing a femoral artery and vein for access to the systemic
circulation. These experiments were carried out while
the dogs were under general anesthesia, induced and
maintained with pentobarbital administered i.v. in the
required amounts. The measurements of U, CR and
MG in muscle tissue were performed on symmetrical,
fresh wet samples of the same muscles (femoral
quadriceps), using the procedure previously de-
scribed [3].
In 8 patients on maintenance peritoneal dialysis and
in 12 on the hemodialysis program (two dialyses per
week of 8 hrs' duration utilizing a multipoint artificial
kidney), the concentrations of U, CR and MG were
measured immediately before dialysis, immediately
after dialysis and 12 hr later, for evaluation of the
phenomenon of plasma rebound.
The binding of MG to plasma proteins was evalu-
ated on eight samples of normal human plasma to
which MG had been added at concentrations ranging
from 100 to 200 g/ml. The pH of an aliquot of this
plasma was adjusted to about 7.3 and that of another
aliquot, to about 7.5, by adding a concentrated solution
of NaCO; each aliquot was then placed in a Cupro-
phane bag (obtained from coil dialyzer tubing) and
each bag was placed in the upper part of a glass tube
having a porous septum across its middle segment.
These were then placed in tubes that were centrifuged
for six hours at 6000 rpm at room temperature. The
MG concentrations were then measured in the plasma
contained in the Cuprophane bags and in the protein-
free ultrafiltrate which collected in the bottom of the
centrifuge tubes. Reproducibility of this procedure was
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determined in six experiments by using the same
plasma samples with added MG, and it was found to
be satisfactory.
Determinations of U, and CR, in plasma samples,
'artificial uremic blood", dialysate (for the experi-
ments reported in Fig. 2) and the aqueous extracts of
muscle tissue of dogs, were performed with an Auto-
analyzer. For measurements of MG, blood samples
were centrifuged immediately after they were drawn so
as to minimize the equilibration of MG between
red blood cells and plasma [8]; plasma was then
frozen until the time of measurement according to the
method previously described [9]. This method is based
on the absorption of MG by a strong cation exchange
resin, from which CR and arginine are removed
completely with a NaOH solution, and MG is then
eluted with HC1. The eluate is evaporated and the
Sakaguchi reaction is performed on the redissolved
dry residue. Activated charcoal is not employed.
Results
The dialyzer clearances of U, CR and MG in vitro
and their dialytic removal from 40 liters of "artificial
uremic blood". The clearance of MG with a standard
two-layer Kiil dialyzer was intermediate between those
of U and CR in all the examined conditions (Fig. 1
and Table I), and it remained constant throughout the
12-hr duration of the experiments. The mean percent
decrease of the MG concentration (—79±3) in 40
liters of "artificial uremic blood" after eight hours of
dialysis with a multipoint hemodialyzer was also
intermediate between that of U (—84±2) and that of
CR (—73 (Table 2).
The dialysis clearances of U, CR and MG in vivo and
the reduction of their plasma concentrations in uremic
patients when treated by various dialytic procedures.
The dialyzer clearance rates of U and CR did not differ
significantly from those observed when "artificial
uremic blood" was examined in vitro (Table 1), and
300
QD, mi/mm
Fig. 1. Standard two-layer Ku! dialyzer clearances of urea, U
(0), creatinine, CR () and methylguanidine, MG (0) obtained
in vitro at different dialysate flow rates (QD), being constant at
200 mi/mm, the flow rate of the "artificial uremic blood".
these values remained constant throughout the dura-
tion of each dialysis. In contrast, the clearance of MG
in vivo at the first measurement was lower (as com-
pared to observations on "artificial uremic blood" in
vitro) 20 mm after the beginning of dialysis (P <0.05 at
QD 200 and P <0.02 at QD 500; Table 1), and it
showed a clear-cut tendency to decrease during the
subsequent course of dialysis (Fig. 2). This fall of the
clearance rate was due to a decrease of the dialyzed
MG which was more rapid than the reduction of its
plasma concentration (Fig. 2). The percent decrease of
the plasma MG concentration after peritoneal dialysis
was lower than after hemodialysis (Table 2, Fig. 3),
and it was also lower than that for U or CR in all the
experiments performed in vivo (Table 2).
The effect of changes of plasma pH on the protein
binding of MG. The percentage of nonultrafiltrable
MG, assumed to correspond to the protein-bound
Table 1. The in vivo and in vitro two-layer Kill dialyzer clearances of urea, creatine and methylguanidine at QB of 200 mI/mm
and at QD of 200 and 500 ml/min
Urea, ml/min Creatinine, mi/mm Methylguanidine, ml/min
QD 200 Q1, 500 200 QD 500 QD 200 QD 500
In vitro
(6 experiments) 64 3 82 2 52 3 63 2 58 3 73 2
In vivo
(9 experiments) 65±6 83±5 54±5 62±6 50±7 65±6
QB, blood flow rate; QD, dialysate flow rate.
80
60E
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Table 2. Percent decreases of urea, creatinine and methylguanidine concentrations obtained on 40 liters of "artificial uremic blood" (AUB)
and on the plasma of uremic patients, with different hemodialytic procedures and with peritoneal dialysis
Experiments
(N)
Urea Creatinine Methylguanidine
Before After Decrease Before After Decrease Before After Decrease
dialysis dialysis % dialysis dialysis % dialysis dialysis %
mg/l00 ml mg/l00 ml mg/l00 ml mg/100 ml ig/l00 ml g/100 ml
8-hr multipoint dialysis,
40litersofAUB 258±58 40±12 —84±2 15±4 4±0.7 —73±4 261±37 54±6 —79±3
(5)
8-hr multipoint dialysis,
uremic patients 240±41 87±27 —64±8 14±3 6±2 —52±6 132±66 68±30 —45±9
twice a week
(28)
I 2-hr, standard two-layer
Kiil, uremic patients 181 41 62±21 —65 5 11 5 5 3 —61 8 128 29 70±14 —44 2
twice a week
(8)
18- to 20-hr peritoneal
dialysis 254±127 158±47 —34±14 15±3 10±3 —29±7 123±60 88±38 27±8
twice a week
(11)
moiety, was significantly higher (P <0.001) at pH
7.51 0.04 (29.6±5.9%) than at pH 7.31 0.03 (15.2
The removal of U, CR and MG from plasma and
muscle tissue of uremic dogs. The concentration of U
in muscle tissue decreased by —67±6%, a value not
significantly different from that observed in plasma
(—67 7). On the contrary, the concentration of CR
and, to a much greater extent, that of MG decreased
much less in muscle tissue than in plasma (P <0.01 for
CR and P<0.00l for MG): muscle tissue CR, —31
11%; plasma CR, —54± 11%; muscle tissue MG,
—24±9%; and plasma MG, —47±15% (Table 3).
Plasma concentrations of U, CR and MG 12 hr after
the termination of hemodialysis and peritoneal dialysis.
Plasma U concentrations 12 hr after the termination
of hemodialysis were lower by 53 7% than pre-
dialysis values; 12 hr after the termination of pen-
toneal dialysis, the plasma U concentrations were
only 27 9% lower (P <0.001). Plasma CR concentra-
tions 12 hr after hemodialysis were lower than those
prior to dialysis by 37 7% and, after peritoneal
dialysis, by 26±7% (P<0,0l). Plasma MG concentra-
tions 12 hr after hemodialysis (—27±8%) were not
significantly different from those observed 12 hr after
peritoneal dialysis (—25±9%) (Fig. 3).
Table 3. The plasma and muscle tissue content of urea, creatinine and methylguanidine of six dogs on their third
Urea Creatinine
Plasma Muscle Plasma
Before
dialysis
mg/l0O ml
After
dialysis
mg/lOO ml
Decrease
%
Before
dialysis
mg/lOO ml
After
dialysis
mg/loom!
Decrease
%
Before
dialysis
mg/lOU ml
After
dialysis
mg/lOU ml
Decrease
%
300
590
500
540
420
420
85
250
130
150
144
160
—71.6
—57.6
—74.0
—72.2
—65.7
—61.9
320
600
490
575
500
450
88
260
125
145
170
165
—72.5
—56.6
—74.5
—74.7
—66.0
—63.3
9.8
19.0
14.0
9.2
12.2
6.6
4.2
11.2
6.0
2.5
6.1
3.5
—57.1
—41.0
—57.1
—72.8
—50.0
—46.9
462 153 —67.1 499 159 —67.9 11.8 5.6 —54.1
±11.0
Fig. 2. Percent decreases of the plasma and dialysate concentra-
tions of MG and the resulting changes of the relative clearances,
occurring in the coarse of hemodialysis with multipoint dialyzers
() (six observations), with standard two-layer Ku! dialyzers (®)
(eight observations) and with peritoneal dialysis (0) (eight
observations).
Discussion
The clearance rates of MG dissolved in water, as
well as the percent decrease of its concentration in 40
liters of "artificial uremic blood" dialyzed for eight
hours, were intermediate between those of U and CR.
That is, the relationship between the clearances of U,
CR and MG were those that would be predicted by
the findings of Babb et al [4] in terms of the relation-
ship between dialyzer clearance rates and the mol wt
of solutes.
Quite different results were obtained in our studies
of uremic patients in vivo. The rates of MG dialyzer
clearance observed in uremic patients 20 mm after
the beginning of hemodialysis were lower than those
obtained in vitro (Table 1), and they decreased further
during the course of dialysis (Fig. 2). The relatively
slow transfer of MG from red blood cells to plasma
[8] and its binding to plasma proteins [10] may well
account for its initially low dialyzer clearance in vivo,
while increased protein binding (occurring as the
plasma pH rises during dialysis [11, 12]) may well
account for the further decrease in clearance during
hemodialysis.
These two factors, each of which may hinder the
dialytic removal of MG from body fluids, offer an
explanation as to why its fractional decrease in the
postdialysis plasma of uremic patients was lower than
that of U and CR, regardless of what dialytic pro-
cedure was employed (Table 2).
However, the main obstacles to the dialytic removal
of MG from body fluids are 1) its preferential distri-
day of anuria, before and after hemodialysis of six hours' duration performed with a two-layer Kiil dialyzer
Methylguanidine
Muscle Plasma Muscle
Before
dialysis
mg/lOU ml
After
dialysis
mg/IOU ml
Decrease Before
dialysis
sg/lO0 ml
After
dialysis
pg/100 ml
Decrease
%
Before
dialysis
sg/1OO ml
After
dialysis
p.g/IOO ml
Decrease
%
15.9
21.1
21.7
21.6
24.2
11.5
12.8
13.9
14.1
12.6
13.8
9,8
—19.4
—34.1
—35.0
—41.6
—42.9
—14.8
90
190
80
70
230
50
40
120
60
25
130
20
—55.5
—36.8
—25.0
—64.3
—43.4
—60.0
300
340
200
220
540
170
260
240
180
160
360
120
—13.3
—29.4
—10.0
—27.3
—33.3
—29.4
19.3 12.8 —31.3 118 66.0 —47.5 295 220 —23.7
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t
C0
C
C0
S
0
12 16 20
Hours Hours Hours Fig. 3. Percent changes of the plasma concentrations of U, CR and
MG at the end () and 12 hr after the termination of hemodialysis
of 8 hr duration made with multipoint dialyzers (0) (12 observa-
tions), at the end (A) ofperitoneal dialysis of 18 to 20 hr duration,
and 12 hr after their termination of dialysis (A) (8 observations).
The white arrows indicate the termination of hemodialysis; the
black arrows indicate the termination of peritoneal dialysis.
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bution in the intracellular fluid compartment [3, 13]
(Table 3); and 2) for hemodialysis, its slow transfer
from the intracellular to the extracellular fluids during
dialysis, a possibility which is suggested directly by the
results of our experiments on uremic dogs (Table 3)
and by those on red blood cells that were carried out
by Babb et al [8].
The very high postdialysis rebound of MG plasma
concentration following a short period of hemodialysis
with high clearance dialyzers is accounted for by this
unique behavior: indeed, it is reasonable to argue that
the transfer of MG from cells continues after the
termination of such dialyses, and that it contributes to
the rapid rose of its plasma concentration (Fig. 3).
The slow transfer of MG from cells to plasma clearly
limits the efficiency of high clearance hemodialysis to
an extent which increases as the plasma MG concen-
tration decreases. Such a barrier to optimal dialytic
removal does not exist for U, and it exists to only a
limited degree for CR, both of which are removed in
amounts that are more strictly related to the clearance
rates of the dialyzers and the duration of dialysis.
In contrast, in the case of peritoneal dialysis where
clearance rates are lower and the procedure is longer
in duration, a continuous equilibrium may develop
between extracellular and intracellular concentrations
of MG, a possibility that is suggested by the occurrence
of a much lower postdialysis rebound of its plasma
concentration (Fig. 3). Thus, the plasma concentration
of MG remains high throughout peritoneal dialysis as
compared to values observed during high clearance
hemodialysis, and it is related more directly to its
concentration within the intracellular pool. It can be
argued that the efficiency of peritoneal dialysis in
removing MG is not limited by its slow transfer from
cells; this accounts for the finding that, despite its
lower clearance, peritoneal dialysis effects the re-
moval of the same amount of MG in 18 to 20 hr as
does high clearance hemodialysis of 8 hrs' duration.
This is shown by the equal reduction of the plasma MG
concentration 12 hr after the end of dialysis at a time
when the distribution of MG in the body fluid com-
partments has presumably reached equilibrium (Fig. 3).
All of this does not occur for U and it occurs to only a
limited extent for CR; consequently, their plasma
concentrations between dialyses remain higher in
patients on peritoneal dialysis than in those on
hemodialysis (Table 2 and Fig. 3).
It is reasonable to suppose that with hemodialysis of
12 hrs' duration, as performed with a standard two-
layer Kiil dialyzer at normal and low Q [6, 7],
intermediate conditions are realized which fall
between those for high clearance hemodialysis of
8 hrs' duration and those for peritoneal dialysis.
It must also be acknowledged that less MG may be
produced by patients on maintenance peritoneal
dialysis than by those who are receiving hemodialysis,
and that such a circumstance might well contribute to
our observed results. However, data have been
recently obtained in our laboratory (unpublished
observations) which are inconsistent with such a
possibility. We administered radioactive CR (14CH3)
to uremic patients; subsequently, radioactive MG was
found in their urine during the following ten days. This
finding suggests that CR may be a metabolic precursor
of MG which accounts for the fact that uremic
patients, having a higher body pool of CR, produce
more MG than normal subjects [3]. It seems quite
unlikely, therefore, that MG production is less in
uremic patients on peritoneal dialysis in view of the
fact that such patients may have a higher poo1 of CR
than those on hemodialysis.
In conclusion, these findings demonstrate that MG
in the body fluids of uremic patients dialyzes quite
differently as compared with U and CR, despite the
fact that their mol wts are similar. It is incorrect,
therefore, to apply conclusions that are derived from
studies of U and CR to predictions regarding MG.
The good clinical condition of patients maintained
on peritoneal dialysis [5] or hemodialysis at low QD
[6, 7], an observation which supports the "middle
molecule hypothesis" because the removal of "postu-
lated toxins" of intermediate mol wt is equally
obtained with these procedures as compared to a
standard hemodialysis schedule, does not discredit
the "MG hypothesis." On the contrary, such clinical
observations might argue in favor of the latter hypo-
thesis since MG is the only known retained meta-
bolite thus far studied whose dialytic removal is
equally obtained with peritoneal dialysis and hemo-
dialysis, as is the case of "middle molecules."
Obviously, this finding does not prove that MG is
important as a "uremic toxin," since other known
and unknown metabolites with a similar dialytic
behavior may also be retained in renal failure.
Definite demonstration of the importance of MG as
a "uremic toxin" in man requires furtherinvestigation.
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